JP2025163031A5 - - Google Patents

Info

Publication number
JP2025163031A5
JP2025163031A5 JP2025113783A JP2025113783A JP2025163031A5 JP 2025163031 A5 JP2025163031 A5 JP 2025163031A5 JP 2025113783 A JP2025113783 A JP 2025113783A JP 2025113783 A JP2025113783 A JP 2025113783A JP 2025163031 A5 JP2025163031 A5 JP 2025163031A5
Authority
JP
Japan
Prior art keywords
seq
liposome
amino acid
acid sequence
helper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025113783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025163031A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/057286 external-priority patent/WO2019084118A2/en
Application filed filed Critical
Publication of JP2025163031A publication Critical patent/JP2025163031A/ja
Publication of JP2025163031A5 publication Critical patent/JP2025163031A5/ja
Pending legal-status Critical Current

Links

JP2025113783A 2017-10-25 2025-07-04 リン酸化タウペプチドの組成物およびその使用 Pending JP2025163031A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762577157P 2017-10-25 2017-10-25
US62/577,157 2017-10-25
PCT/US2018/057286 WO2019084118A2 (en) 2017-10-25 2018-10-24 PHOSPHORYLATED TUBE PEPTIDE COMPOSITIONS AND USES THEREOF
JP2020523284A JP7550643B2 (ja) 2017-10-25 2018-10-24 リン酸化タウペプチドの組成物およびその使用
JP2023018374A JP7793562B2 (ja) 2017-10-25 2023-02-09 リン酸化タウペプチドの組成物およびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023018374A Division JP7793562B2 (ja) 2017-10-25 2023-02-09 リン酸化タウペプチドの組成物およびその使用

Publications (2)

Publication Number Publication Date
JP2025163031A JP2025163031A (ja) 2025-10-28
JP2025163031A5 true JP2025163031A5 (https=) 2026-02-24

Family

ID=64362628

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020523284A Active JP7550643B2 (ja) 2017-10-25 2018-10-24 リン酸化タウペプチドの組成物およびその使用
JP2023018374A Active JP7793562B2 (ja) 2017-10-25 2023-02-09 リン酸化タウペプチドの組成物およびその使用
JP2025113783A Pending JP2025163031A (ja) 2017-10-25 2025-07-04 リン酸化タウペプチドの組成物およびその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020523284A Active JP7550643B2 (ja) 2017-10-25 2018-10-24 リン酸化タウペプチドの組成物およびその使用
JP2023018374A Active JP7793562B2 (ja) 2017-10-25 2023-02-09 リン酸化タウペプチドの組成物およびその使用

Country Status (25)

Country Link
US (4) US11958889B2 (https=)
EP (1) EP3700556A2 (https=)
JP (3) JP7550643B2 (https=)
KR (2) KR102710762B1 (https=)
CN (2) CN117298259A (https=)
AR (1) AR113792A1 (https=)
AU (2) AU2018355325B2 (https=)
BR (1) BR112020008168A2 (https=)
CA (2) CA3079423A1 (https=)
CL (2) CL2020001070A1 (https=)
CO (1) CO2020006073A2 (https=)
CR (1) CR20240219A (https=)
DO (1) DOP2020000135A (https=)
EA (1) EA202091012A1 (https=)
EC (1) ECSP20026986A (https=)
IL (2) IL273980B2 (https=)
JO (1) JOP20200103A1 (https=)
MA (1) MA50465A (https=)
MX (2) MX2020004338A (https=)
MY (1) MY202233A (https=)
PH (1) PH12020550432A1 (https=)
SA (1) SA520411820B1 (https=)
SG (1) SG11202003556UA (https=)
TW (2) TWI827557B (https=)
WO (1) WO2019084118A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102710762B1 (ko) * 2017-10-25 2024-09-25 얀센 파마슈티칼즈, 인코포레이티드 인산화 타우 펩티드의 조성물 및 이의 용도
WO2020123492A1 (en) * 2018-12-10 2020-06-18 New York University Monoclonal antibodies targeting c-terminal region of phosphorylated tau
AU2020219804A1 (en) 2019-02-08 2021-08-19 Ac Immune S.A. Method of safe administration of phosphorylated Tau peptide vaccine
EA202192891A1 (ru) * 2019-04-24 2022-02-04 Янссен Фармасьютикалз, Инк. Гетерологичное введение анти-тау вакцин
JP7702381B2 (ja) * 2019-07-08 2025-07-03 アルゼカ バイオサイエンシズ、エルエルシー タウ病理のためのターゲティングリガンド
CA3152239A1 (en) * 2019-09-23 2021-04-01 Lars Ittner Treatment of tauopathies
WO2021126281A1 (en) 2019-12-20 2021-06-24 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof
US20230131808A1 (en) * 2020-04-22 2023-04-27 Southlake Pharmaceuticals, Inc. Pegylated interferon tau and compositions and methods thereof
JP7687699B2 (ja) * 2020-09-08 2025-06-03 国立大学法人大阪大学 リン酸化タウタンパク質を標的とする免疫原性組成物
JP2023541671A (ja) * 2020-09-17 2023-10-03 プロシーナ バイオサイエンシーズ リミテッド シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン
JP2024532787A (ja) * 2021-08-12 2024-09-10 ヤンセン ファーマシューティカルズ，インコーポレーテッド 持続的な免疫応答を誘導するためのリン酸化タウペプチドを含むリポソーム
WO2023056369A1 (en) * 2021-09-29 2023-04-06 Janssen Pharmaceuticals, Inc. Method of safe administration of tau phosphopeptide conjugate
US20250152684A1 (en) * 2022-02-09 2025-05-15 Ac Immune Sa Anti-Alpha-Synuclein Therapeutic Vaccines
AU2023307073A1 (en) * 2022-07-14 2025-02-27 Vaxxinity, Inc. Tau peptide immunogen constructs
WO2025090815A1 (en) * 2023-10-24 2025-05-01 Janssen Pharmaceuticals, Inc. Method of treating preclinicial alzheimer's disease
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
DE69318420T2 (de) 1992-12-14 1999-01-28 Naamloze Vennootschap Innogenetics S.A., Gent Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US20020086009A1 (en) 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
KR20010032753A (ko) 1997-12-03 2001-04-25 온토제니, 인코오포레이티드 소수적으로 개질된 단백질 조성물 및 방법
US6314469B1 (en) 1999-02-26 2001-11-06 I-Dns.Net International Pte Ltd Multi-language domain name service
CA2415919A1 (en) 2000-07-11 2002-01-17 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
GB0114719D0 (en) 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
EP1474432A1 (en) 2002-02-04 2004-11-10 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
JP4662719B2 (ja) 2002-04-19 2011-03-30 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント アルツハイマー病の処置のための免疫学的方法および組成物
EP1585520A1 (en) 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
EP1691666B1 (en) 2003-12-12 2012-05-30 University of Washington Catheterscope 3d guidance and interface system
US20050261475A1 (en) 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
NZ562434A (en) 2005-05-05 2010-04-30 Merck & Co Inc Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
CA2633399C (en) 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
WO2007068105A1 (en) 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
JP5823663B2 (ja) 2006-03-03 2015-11-25 プロミス ニューロサイエンシズ インコーポレイテッド ミスフォールドｓｏｄ１媒介疾患を処置および検出するための方法および組成物
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
JPWO2009051220A1 (ja) 2007-10-19 2011-03-03 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
US9498522B2 (en) 2008-08-07 2016-11-22 Mercia Pharma Inc. Immunotherapeutic compositions for the treatment of alzheimer'S disease
CN102365295A (zh) 2009-01-30 2012-02-29 阿德利夫股份有限公司 构象动力肽
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
SI2408807T1 (sl) * 2009-03-18 2021-11-30 Ac Immune Sa Postopek za terapevtsko uporabo
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
NZ598356A (en) 2009-07-30 2014-06-27 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
WO2011032155A2 (en) 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
RU2664452C2 (ru) 2010-04-19 2018-08-17 Нлифе Терапеутикс, С.Л. Конъюгат, медицинское средство и способы лечения и/или профилактики депрессии и болезни, связанной с отложением телец Леви
EP3527220A1 (en) * 2010-08-12 2019-08-21 AC Immune S.A. Vaccine engineering
AR083561A1 (es) 2010-10-26 2013-03-06 Ac Immune Sa Preparacion de una construccion antigenica
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
ES2656442T3 (es) * 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
US20140314837A1 (en) 2011-09-23 2014-10-23 Ac Immune S. A. Vaccine Therapy
WO2013058350A1 (ja) 2011-10-21 2013-04-25 三菱化学株式会社 周期表第１３族金属窒化物半導体結晶の製造方法、及び該製造方法により製造される周期表第１３族金属窒化物半導体結晶
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US20170368167A9 (en) * 2012-08-21 2017-12-28 The Institute For Molecular Medicine Compositions and methods related to neurological disorders
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
WO2015197820A1 (en) 2014-06-26 2015-12-30 Crucell Holland B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EP4465050A3 (en) 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
CA2988436A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
CN108024698B (zh) 2015-08-14 2020-09-15 直观外科手术操作公司 用于图像引导外科手术的配准系统和方法
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
MA48595A (fr) 2016-12-07 2020-03-18 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
KR102710762B1 (ko) 2017-10-25 2024-09-25 얀센 파마슈티칼즈, 인코포레이티드 인산화 타우 펩티드의 조성물 및 이의 용도
EP3706795A4 (en) 2017-11-09 2021-10-13 Pinteon Therapeutics Inc. METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
AU2020219804A1 (en) * 2019-02-08 2021-08-19 Ac Immune S.A. Method of safe administration of phosphorylated Tau peptide vaccine
EA202192891A1 (ru) 2019-04-24 2022-02-04 Янссен Фармасьютикалз, Инк. Гетерологичное введение анти-тау вакцин

Similar Documents

Publication Publication Date Title
JP2025163031A5 (https=)
IL273980B1 (en) Compositions of phosphorylated tau peptides and uses thereof
US7741297B2 (en) Immunostimulatory, covalently lipidated oligonucleotides
US9717685B2 (en) Lipid-coated nucleic acid nanostructures of defined shape
EP1326636B1 (fr) Composition vaccinale
US11684576B2 (en) Method of safe administration of phosphorylated tau peptide vaccine
JP5165681B2 (ja) タンパク質断片又はペプチドカクテルとして送達される抗原を用いたワクチン接種によるサブドミナントエピトープを含むｔ細胞レパートリーの拡大
JP2014513946A (ja) 筋強直性ジストロフィー１型（ｄｍ１）などのヒト遺伝性疾患の治療、遅延及び／又は予防のための新規の化合物
JP2021517471A5 (https=)
WO2021061537A1 (en) Vaccine therapy for ran protein diseases
EP2300494A1 (en) Anti-amyloid immunogenic compositions, methods and uses
JPWO2019084118A5 (https=)
JPWO2020163730A5 (https=)
WO2012141280A1 (ja) Ｄｎａワクチン
JPWO2020219646A5 (https=)
EP1505942B1 (en) Pathogen vaccines and methods for using the same
CA2204618A1 (fr) Proteine g du virus respiratoire syncytial exprimee sur membrane bacterienne
WO2022174151A1 (en) Prophylactic broad spectrum vaccine for sars-cov-2
US20250144212A1 (en) Liposomes containing phosphorylated tau peptides for inducing sustained immune responses
JPWO2023019241A5 (https=)
CN118660717A (zh) 抗α-突触核蛋白的治疗性疫苗
HK40061379A (en) Method of safe administration of phosphorylated tau peptide vaccine
JPWO2023022973A5 (https=)
CN120583938A (zh) 脂质体构建体
EA045311B1 (ru) Способ безопасного введения вакцины фосфорилированного пептида tau